(0.28%) 5 114.35 points
(0.36%) 38 376 points
(0.34%) 15 982 points
(-1.59%) $82.52
(5.36%) $2.03
(0.28%) $2 353.70
(0.25%) $27.61
(3.99%) $958.85
(-0.21%) $0.933
(-0.35%) $10.99
(-0.53%) $0.796
(1.68%) $93.42
12.76% $ 13.18
@ $0.740
Ausgestellt: 13 Feb 2024 @ 18:37
Rendite: 1 681.32%
Vorheriges Signal: Feb 13 - 17:13
Vorheriges Signal:
Rendite: 0.58 %
Live Chart Being Loaded With Signals
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies...
Stats | |
---|---|
Tagesvolumen | 2.16M |
Durchschnittsvolumen | 726 115 |
Marktkapitalisierung | 276.07M |
EPS | $0 ( 2024-03-14 ) |
Nächstes Ertragsdatum | ( $-3.10 ) 2024-05-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.960 |
ATR14 | $0.0680 (0.52%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-05 | Hirsch Susan B | Buy | 5 000 | Stock Option |
2024-02-05 | Wiinberg Ulf | Buy | 5 000 | Stock Option |
2024-02-05 | Corvese Brian | Buy | 15 000 | Stock Option |
2024-02-05 | Jeynes-ellis Allison M | Buy | 5 000 | Stock Option |
2024-02-05 | Wright Timothy | Buy | 7 500 | Stock Option |
INSIDER POWER |
---|
100.00 |
Last 98 transactions |
Buy: 11 279 188 | Sell: 367 647 |
Volumen Korrelation
Agenus Inc Korrelation
10 Am meisten positiv korreliert | |
---|---|
BTTX | 0.967 |
OMCL | 0.963 |
CDMO | 0.962 |
SCPH | 0.961 |
SVRE | 0.957 |
SILK | 0.957 |
OMER | 0.956 |
LIFE | 0.951 |
LITM | 0.951 |
CFRX | 0.951 |
10 Am meisten negativ korreliert | |
---|---|
FRSG | -0.974 |
IVCB | -0.973 |
TBSA | -0.97 |
LEGA | -0.968 |
CPAQ | -0.968 |
AHRN | -0.967 |
LGAC | -0.967 |
FTPA | -0.967 |
ACQR | -0.966 |
HORI | -0.966 |
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Agenus Inc Korrelation - Währung/Rohstoff
Agenus Inc Finanzdaten
Annual | 2023 |
Umsatz: | $156.31M |
Bruttogewinn: | $139.62M (89.32 %) |
EPS: | $-0.690 |
FY | 2023 |
Umsatz: | $156.31M |
Bruttogewinn: | $139.62M (89.32 %) |
EPS: | $-0.690 |
FY | 2022 |
Umsatz: | $98.02M |
Bruttogewinn: | $-99.24M (-101.24 %) |
EPS: | $-0.960 |
FY | 2021 |
Umsatz: | $295.67M |
Bruttogewinn: | $113.59M (38.42 %) |
EPS: | $-0.110 |
Financial Reports:
No articles found.
Agenus Inc
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, the company develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS, as well as in clinical stage to treat hematological malignancies and multiple myeloma/B cells; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. Agenus Inc. operates under ASV, Agenus, AutoSynVax, EVAMPLIX, MiNK, PSV, PhosPhoSynVax, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.